(Q34655730)

3 August 2017

Febrile neutropenia in hematologic malignancies (English)

1 reference

3 August 2017

Michael K Keng

1

1 reference

PubMed ID

23990311

3 August 2017

Mikkael A Sekeres

series ordinal

2

1 reference

3 August 2017

1 December 2013

1 reference

Current hematologic malignancy reports

3 August 2017

1 reference

3 August 2017

8

1 reference

3 August 2017

4

1 reference

3 August 2017

370-378

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-013-0171-4

3 August 2017

0 references

cites work

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Survival in neutropenic patients with severe sepsis or septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Management of fever in patients with cancer and treatment-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

The treatment of febrile neutropenia: from the Dark Ages to the present

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Controversies in new antibiotic therapy for ambulatory patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Risk models for predicting chemotherapy-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Management of febrile neutropenia: ESMO Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Normal hospital and low-bacterial diet in patients with cytopenia after intensive chemotherapy for hematological malignancy: a study of safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Utility of influenza vaccination for oncology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Viral hepatitis: manifestations and management strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Diagnosis and management of infectious complications in critically ill patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Bacteraemia in febrile neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0171-4

Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group

21 January 2018

1 reference

12 December 2020

Point: fluoroquinolone-based antibacterial chemoprophylaxis in neutropenic cancer patients works for defined outcomes in defined populations, but must be used wisely.

1 reference

12 December 2020

Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule

1 reference

12 December 2020

Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome

1 reference

12 December 2020

Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence

1 reference

12 December 2020

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

1 reference

12 December 2020

Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score

1 reference

12 December 2020

Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.

1 reference

12 December 2020

Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study

1 reference

12 December 2020

Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients

1 reference

12 December 2020

A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma

1 reference

12 December 2020

Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment

1 reference

12 December 2020

The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation

1 reference

12 December 2020

Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma

1 reference

12 December 2020

The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study

1 reference

12 December 2020

Outpatient therapy for febrile neutropenia

1 reference

12 December 2020

Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule

1 reference

12 December 2020

10.1007/S11899-013-0171-4

Identifiers

DOI

1 reference

PubMed ID

23990311

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

23990311